Rank |
Status |
Study |
1 |
Recruiting
|
Tetracycline as a Prophylaxis for RASH in Patients With NSCLC Receiving Treatment With BIBW 2992
Conditions: |
Skin RASH; Lung Cancer |
Intervention: |
Drug: Tetracycline |
Outcome Measures: |
Incidence and severity of RASH; Quality of life; RASH and progression free-survival; RASH and overall survival |
|
2 |
Recruiting
|
1% Topical Pimecrolimus Cream for the Treatment of the RASH Associated With ERBITUX
Condition: |
RASH |
Intervention: |
Drug: Pimecrolimus |
Outcome Measures: |
Prevention of cetuximab RASH; Quality of Life |
|
3 |
Not yet recruiting
|
Determination of Safety and Consumers' Satisfaction of Moussik Versus Desitin Creamy Ointment in Diaper RASH Prophylaxis
Condition: |
Diaper RASH |
Interventions: |
Other: Moussik Diaper RASH Mousse; Other: Desitin Creamy Ointment |
Outcome Measures: |
Six point erythema skin grade; Visual analogue scale (VAS) from 0 to 10 |
|
4 |
Recruiting
|
Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream Lotion, for EGFR'I Induced Acneiform RASH
Condition: |
Acneiform RASH |
Interventions: |
Drug: Threolone ointment; Drug: ointment Synthomycine; Drug: Aqua cream lotion |
Outcome Measures: |
Number of patients developing grade 2 / above RASH under preventative treatment with ointment threolone, compared to the other 2 treatment arms.; Number of patients developing a RASH under preventative treatment with ointment threolone, compared to the other 2 treatment arms |
|
5 |
Recruiting
|
Skin RASH Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
Conditions: |
Colorectal Cancer; Head and Neck Cancer |
Interventions: |
Drug: Doxycycline; Drug: Hydrocortisone 1% cream; Other: Sunscreen; Other: Moisturizer; Drug: Clindamycin; Drug: Medrol-dose pack (Steroid) |
Outcome Measures: |
Incidence of RASH; Quality of Life (QOL); Adherence to treatment regimen; Progression Free Survival |
|
6 |
Recruiting
|
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) RASH in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Conditions: |
Cetuximab-induced Papulopustular (Acneiform) RASH Who Have; Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma |
Interventions: |
Drug: Topical Dapsone 5% Gel; Other: Moisturizer; Drug: oral antibiotics |
Outcome Measure: |
difference in lesion counts |
|
7 |
Not yet recruiting
|
Evaluation of the Quality of Self-collected Blood Spot Specimens for Laboratory HIV Testing - An InvolveMENt Sub Study
Conditions: |
HIV; Dried Blood Spot Method |
Intervention: |
Other: Number of DBS Spots |
Outcome Measure: |
Viable sample for HIV Testing |
|
8 |
Recruiting
|
Regulatory T Cells (Tregs) in Polymorphic Light Eruption
Conditions: |
Polymorphic Light Eruption; Psoriasis; Atopic Eczema |
Intervention: |
|
Outcome Measures: |
Treg level and function; Blood and/or skin cytokine and chemokine levels, vitamin D status, and other immunoregulatory parameters (see above) |
|
9 |
Recruiting
|
Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer
Condition: |
Metastatic Pancreatic Adenocarcinoma |
Interventions: |
Drug: Gemcitabine; Drug: Erlotinib; Drug: Oxaliplatin; Drug: Folinic Acid; Drug: Irinotecan; Drug: 5-FU |
Outcome Measures: |
1-year Survial rate of "good-risk" patients; Evalutation of overall response rate, disease control rate and progression free survival; Evaluation of adverse events; Translational Projects |
|
10 |
Unknown †
|
The Spot Sign for Predicting and Treating ICH Growth Study
Condition: |
Intracerebral Hemorrhage |
Interventions: |
Drug: recombinant activated factor VII; Drug: placebo |
Outcome Measures: |
Life-threatening thromboembolic complications defined as development of (1) acute myocardial ischemia; (2) acute cerebral ischemia; and (3) acute pulmonary embolism; The rate of hematoma growth among spot sign positive subjects at 24 hours, comparing subjects treated with rFVIIa to those treated with placebo. Hematoma growth will be defined as a > 33% or > 6 cc increase in volume.; The sensitivity and specificity of the spot sign for predicting hematoma growth; Incidence of other potentially study drug related thromboembolic complications such as deep venous thrombosis and elevations in troponin not associated with ECG changes; Ninety-day outcomes among spot positive subjects, dichotomized as modified Rankin Scale score of 0-4 verses 5-6, comparing subjects treated with rFVIIa to those treated with placebo; The positive and negative predictive values of the spot sign and the accuracy of the site investigators for correct identification of the spot sign as compared to a blinded study neuroradiologist.; Rate of total hemorrhage volume growth (hematoma + IVH) among spot-positive subjects. |
|
11 |
Unknown †
|
Regenecare® Wound Gel in Treating RASH in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer
Conditions: |
Dermatologic Complications; Unspecified Adult Solid Tumor, Protocol Specific |
Intervention: |
Dietary Supplement: collagen/aloe vera/vitamin E/lidocaine topical hydrogel |
Outcome Measures: |
Efficacy of Regenecare® wound gel, in terms of alleviating pain and itching; Efficacy of Regenecare® wound gel, in terms of reducing severity, redness, and appearance of RASH; Tolerability of Regenecare® wound gel as assessed by NCI CTCAE v3.0 |
|
12 |
Recruiting
|
Vitamin D Supplementation in Polymorphic Light Eruption
Condition: |
Polymorphic Light Eruption |
Interventions: |
Drug: Oral Vitamin D 3; Drug: Miglyol 812 N |
Outcome Measures: |
PLE test score (from 0-12) of experimental photo provocation; Cytokine levels in serum; Chemotaxis of neutrophils; Level of regulatory T cells; Quantification of skin alterations, including cellular infiltration and cytokine profile; Dermatological quality of life (DLQI); HADS (hospital anxiety and depression scale); Function of regulatory T cells |
|
13 |
Not yet recruiting
|
Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous RASH Treatment
Condition: |
Cutaneous Hypersensitivity |
Interventions: |
Drug: Desloratadine + Prednisolone; Drug: Dexchlorpheniramine + Betamethasone |
Outcome Measures: |
Efficacy of treatment in acute cutaneous RASH based on symptoms score; Safety will be evaluated by the adverse event occurrences |
|
14 |
Unknown †
|
Does Acne RASH During Adolescence Predict Skin Reaction to Cetuximab
Condition: |
Colorectal Cancer Metastatic |
Intervention: |
Drug: Cetuximab |
Outcome Measure: |
|
|
15 |
Recruiting
|
Study of Procoagulation Markers in Stroke Patients
Conditions: |
Stroke; Hyperglycemia; Procoagulation Markers |
Intervention: |
Other: Glycemic Control |
Outcome Measures: |
change in biomarker between patients with favorable versus unfavorable functional outcome; Changes in biomarker levels between patients with versus without stroke recurrence at 90 days post stroke. |
|
16 |
Unknown †
|
An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots
Condition: |
HIV Infections |
Intervention: |
Drug: HEC placebo gel |
Outcome Measures: |
Presence or absence of bare spots with and without Gd.; Quantification and location of bare spots. |
|
17 |
Not yet recruiting
|
A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI
Condition: |
RASH Due to Epidermal Growth Factor Receptor Inhibitors |
Interventions: |
Drug: RECONVAL CREAM; Drug: PLACEBO |
Outcome Measure: |
Potential reduction in skin toxicity by Vitamin K1 cream in metastatic colorectal patients treated with EGFRI |
|
18 |
Unknown †
|
Elmex Gel Efficacy in Preventing White Spot Lesions
Condition: |
Dental Caries |
Intervention: |
Drug: elmex gel |
Outcome Measures: |
time and frequency of visually detected WSL (white spot lesions); mineral loss according to QLF readings; Frequency and chronoloy of WSL |
|
19 |
Recruiting
|
Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI)
Conditions: |
Cancer; Skin RASH |
Intervention: |
Other: cream |
Outcome Measures: |
grade 2 or more papulopustular eruption; impact of papulopustular eruptions on HRQoL; patient tolerability and satisfaction of study cream; effectiveness of study cream on the adherence; other dermatological side effects |
|
20 |
Not yet recruiting
|
Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy
Condition: |
HIV/AIDS |
Intervention: |
|
Outcome Measures: |
Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with HIV viral suppression at study visit #1 (initial study visit).; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with HIV viral suppression at study visit #2.; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with HIV viral suppression at study visit #3.; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with self-reported adherence at study visit #1 (initial study visit).; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with self-reported adherence at study visit #2.; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with self-reported adherence at study visit #3.; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with pharmacy refill adherence at study visit #1 (initial study visit).; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with pharmacy refill adherence at study visit #2.; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with pharmacy refill adherence at study visit #3.; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with and elevation in serum creatinine at study visit #1 (initial study visit).; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with and elevation in serum creatinine at study visit #2.; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with and elevation in serum creatinine at study visit #3.; Level of TFV-DP in DBS in participants with wild-type vs. single nucleotide polymorphisms in ABCC2 (-24C>T, 1249G>A), ABCC4 (1612C>T, 3463G>A, 3724G>A, 4131T>G), and other relevant genes for tenofovir at study visit #1 (initial study visit).; Level of TFV-DP in DBS in participants with wild-type vs. single nucleotide polymorphisms in ABCC2 (-24C>T, 1249G>A), ABCC4 (1612C>T, 3463G>A, 3724G>A, 4131T>G), and other relevant genes for tenofovir at study visit #2.; Level of TFV-DP in DBS in participants with wild-type vs. single nucleotide polymorphisms in ABCC2 (-24C>T, 1249G>A), ABCC4 (1612C>T, 3463G>A, 3724G>A, 4131T>G), and other relevant genes for tenofovir at study visit #3.; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) at study visit #1 associated with HIV viral suppression at study visits #2 and #3.; Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) at study visit #2 associated with HIV viral suppression at study visit #3. |
|